A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers.
Igor E MakarenkoArtem DorotenkoSergey NoskovVeniamin BankoValeria SaparovaAlexandr KhokhlovEvgeniia ZoreevaAndrey NedorubovBella ZinnatulinaMaria GefenRoman V DraiPublished in: Pharmacology research & perspectives (2023)
This study demonstrates the PD similarity of GP40141 to the reference romiplostim. Both treatments had comparable safety profiles (NCT05652595).